Kurt R. Gehlsen MD, PhD

Dr. Kurt Gehlsen is the Founder and Chairman of MIRA Life Science Ventures, he is also a business owner of Gehlsen Consulting. Dr. Gehlsen was Vice President and CSO of Research Corporation Technologies (RCT), an early-stage investment and development firm in Tucson, AZ from 2005 to 2018. Dr. Gehlsen was Senior Vice President, Development, and Chief Scientific Officer at Maxim Pharmaceuticals, a public San Diego biopharmaceutical company from 1996 to 2004 and developed CepleneTM as the first immune-oncology drug to be approved as a remission maintenance therapy for AML.